We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01550926
First Posted: March 12, 2012
Last Update Posted: January 28, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
November 17, 2011
March 12, 2012
January 28, 2013
February 2009
March 2009   (Final data collection date for primary outcome measure)
Fecal fat excretion [ Time Frame: 9 days ]
Same as current
Complete list of historical versions of study NCT01550926 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
The purpose of this study is to determine whether a new dosage form and dose of orlistat is equivalent to the currently marketed form.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Overweight
  • Drug: 120 mg orlistat
    2 X60 mg capsule
  • Drug: 60 mg orlistat
    60 mg orlistat
  • Drug: orlistat experimental dose
    experimental
  • Active Comparator: Arm 1
    60 mg orlistat
    Intervention: Drug: 60 mg orlistat
  • Active Comparator: Arm 2
    120 mg orlistat (2 X 60 mg capsules)
    Intervention: Drug: 120 mg orlistat
  • Experimental: Arm 3
    orlistat experimental formulation
    Intervention: Drug: orlistat experimental dose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
March 2009
March 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • age: 18-60 years
  • Body Mass Index: 25-33

Exclusion Criteria:

  • gastrointestinal disease
  • organ transplant
  • HIV, hepatitis B or C
  • food allergies
  • alcohol or other substance abuse
  • smoking
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT01550926
W3680604
No
Not Provided
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP